Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: preceding (28), earlier (169), prior (757)

Fluorouracil-Folinic Acid-Irinotecan-Oxaliplatin

Description: Chemotherapy Protocol PANCREATIC CANCER FLUOROURACIL-FOLINIC ACID-IRINOTECAN-OXALIPLATIN
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Pancreas/Fluorouracil-Folinic-Acid-Irinotecan-Oxaliplatin.pdf

Finance and Performance Reports 2023-24 Month 10 - January 2024

Description: Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose: Finance Report 2023-24 Month 10 10.3 Ian Howard –
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Finance-and-Performance-Reports-2023-24-Month-10-January-2024.pdf

Tisacel -Cyclophosphamide (250)-Fludarabine (25)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY DLBCL/ FL – TISACEL – FLUDARABINE (25) – CYCLOPHOSPHAMIDE (250) Regimen Thi
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Tisacel-Cyclophosphamide-250-Fludarabine-25.pdf

Epi for Clinicians 2023 Advert

Description: EPIDEMIOLOGY FOR CLINICIANS A practical introduction to epidemiological research An introduction to epidemiology for those wanting t
Url: /Media/Southampton-Clinical-Research/Downloads/Epi-for-Clinicians-2023-Advert.pdf

UHS AR 21-22 Quality Account

Description: QUALITY ACCOUNT 2021/22 Part 1: QStaUteAmeLnItToYn qAuaClitCy fOroUm NtheTchief executive 2021/22 1.1 Chief executive’s statement an
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/UHS-AR-21-22-Quality-Account.pdf

Pembrolizumab 400mg (bladder)

Description: Chemotherapy Protocol BLADDER CANCER Pembrolizumab (400mg) Regimen • Bladder – Pembrolizumab (400mg) Indication • Pembrolizumab is indicated for locally advanced (ie T4b
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-400mg.pdf

Pembrolizumab 200mg (bladder)

Description: Chemotherapy Protocol BLADDER CANCER Pembrolizumab (200mg) Regimen • Bladder – Pembrolizumab (200mg) Indication • Pembrolizumab is indicated for locally advanced (ie T4b
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-200mg.pdf

InP-Ifosfamide-Liposomal Doxorubicin (Caelyx) v1

Description: Chemotherapy Protocol SARCOMA IFOSFAMIDE-LIPOSOMAL DOXORUBICIN (Caelyx) In-Patient Regimen Please note this prot
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/InP-Ifosfamide-Liposomal-Doxorubicin-Caelyx-v1.pdf

Engaging for increased research participation - full report

Description: Engaging for increased research participation Public and healthcare professionals' perceptions For further information contact: Chris Stock Head o
Url: /Media/Southampton-Clinical-Research/Marketresearch/Engaging-for-increased-research-participation-full-report-v2.pdf

Appendix K - HAV information re post-exposure treatment

Description: HAV,post-exposure
Url: /Media/UHS-website-2019/Docs/Post-Exposure-Prophylaxis-Policy/AppendixK-HAVinformationrepostexposuretreatment.pdf

111 to 120 of 489

Previous … 10 11 12 13 14 … Next